#China #Shenzhen #Medical Devices #LifeTech Scientific #Cardio-Cerebrovascular

LifeTech Scientific Corporation's Buzzer Report for 2026

LifeTech Scientific Corporation, known for its commitment to developing innovative medical solutions, has revealed its interim financial results for the first half of 2026. With a stock code of 1302.HK, LifeTech's performance reveals significant growth, particularly in the face of increasing challenges within the global medical device market.

During the first half of 2026, LifeTech achieved a revenue of approximately RMB 600.8 million, marking a remarkable achievement for the medical device company, which specializes in creating minimally invasive interventional solutions aimed at treating cardio-cerebrovascular and peripheral vascular diseases. This revenue includes a gross profit of around RMB 465.9 million and a gross profit margin that has increased by 3.9 percentage points to 77.5%.

Net profit attributable to the company owners was around RMB 114.8 million, suggesting strong operational efficacy despite the complexities of the market. Notably, the company's cash reserves stand at about RMB 953.8 million, reflecting a significant increase of approximately 32.6% since December 2025. This solid financial footing allows LifeTech to further invest in research and development, vital for continuing innovation and product enhancement.

Strategic Focus Towards Growth

In addressing unmet clinical needs globally, LifeTech has strategically leveraged its brand synergies, intellectual property, and extensive distribution networks. Its continued commitment to innovation and quality has enhanced its product portfolio, which now includes cutting-edge solutions tailored for various vascular diseases, demonstrating their assertion of a global market position.

Notably, the domestic market within China's mainland continues to be the company's most significant revenue contributor, accounting for about 69.6% of total revenue during the reporting period. The growth in overseas sales reflects a year-on-year increase of around 4.1%, with the company's operations in Asia and Europe becoming key international revenue streams.

Diversification and Focus on Core Markets

LifeTech's commitment to innovation culminates in addressing the challenges presented by structural heart diseases and peripheral vascular diseases. The company's diverse product offerings have catered to these critical areas, with the Structural Heart Diseases (SHD) segment generating approximately RMB 200.1 million in sales. The Peripheral Vascular Diseases (PVD) sector particularly stood out, recording sales of RMB 400.7 million, just shy of a 2.3% year-on-year increase.

Investment in Future Growth

In alignment with its growth strategies, LifeTech invested around RMB 167.1 million in research and development during the reporting period—an essential step towards reinforcing its market leadership. The continuous growth in its innovative capability aims to yield new products like advanced stent graft systems and occluders, targeting different vascular conditions.

Moreover, LifeTech is not resting on its laurels. A variety of products are currently pending certification across regulatory bodies, evidencing the company’s operational vigor and willingness to push the envelope toward higher standards in medical device engineering.

Mr. XIE Yuehui, LifeTech’s Chairman and CEO, stated, “Despite facing external volatility, we remain focused on innovation and international market expansion. The strength of our product mix is improving, which is crucial for our sustainable growth.”

Continued success in both domestic and overseas markets positions LifeTech as a leader in the medical device landscape, showcasing its resilience amid industry transformations. Looking ahead, the company remains steadfast in its dedication to addressing health challenges while creating value for patients, healthcare institutions, and stakeholders alike.